Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Acumen Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ABOS
Nasdaq
8731
https://acumenpharm.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Acumen Pharmaceuticals Inc
12 Cheap Foods With Anti-Aging Properties That Longevity Scientists Swear By
- Apr 19th, 2024 4:13 pm
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
- Apr 16th, 2024 12:00 pm
13 Best Penny Stocks to Buy According to Billionaire Ken Griffin
- Apr 8th, 2024 9:38 pm
Acumen Pharmaceuticals Collaborates with Lonza For Alzheimer’s Treatment
- Apr 4th, 2024 6:12 pm
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease
- Apr 4th, 2024 12:00 pm
Why Acumen Pharmaceuticals (ABOS) Stock Might be a Great Pick
- Apr 3rd, 2024 12:38 pm
Acumen Pharmaceuticals (ABOS) Upgraded to Buy: What Does It Mean for the Stock?
- Mar 28th, 2024 4:00 pm
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2023 Earnings Call Transcript
- Mar 27th, 2024 1:46 pm
Q4 2023 Acumen Pharmaceuticals Inc Earnings Call
- Mar 27th, 2024 1:20 am
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights
- Mar 26th, 2024 11:00 am
Is Acumen Pharmaceuticals (ABOS) Outperforming Other Medical Stocks This Year?
- Mar 21st, 2024 2:41 pm
Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting
- Mar 21st, 2024 12:00 pm
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024
- Mar 19th, 2024 8:00 pm
15 Best Anti-Aging Foods for Youthful Skin
- Mar 18th, 2024 2:31 pm
Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days
- Mar 12th, 2024 8:00 pm
Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
- Mar 8th, 2024 1:50 pm
Has Acumen Pharmaceuticals (ABOS) Outpaced Other Medical Stocks This Year?
- Feb 29th, 2024 2:40 pm
Institutional investors own a significant stake of 42% in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS)
- Feb 24th, 2024 1:10 pm
Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting
- Feb 21st, 2024 1:00 pm
Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer
- Feb 1st, 2024 12:00 pm
Scroll